Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
Stock Snapshot
The current Merck(MRK) stock price is $101.48, with a market capitalization of 251.89B. The stock trades at a price-to-earnings (P/E) ratio of 13.36 and offers a dividend yield of 3.2%.
During the trading session on 2025-12-04, Merck(MRK) shares reached a daily high of $102.67 and a low of $100.84. At a current price of $101.48, the stock is +0.6% higher than the low and still -1.2% under the high.
Trading volume for Merck(MRK) stock has reached 2.04M, versus its average volume of 15.82M.
Over the past 52 weeks, Merck(MRK) stock has traded between a high of $105.84 and a low of $73.31.
Over the past 52 weeks, Merck(MRK) stock has traded between a high of $105.84 and a low of $73.31.
MRK News
Merck & Co., Inc. ( ) will increase its dividend from last year's comparable payment on the 8th of January to $0.85. This takes the dividend yield to 3.3%, whic...
Merck & Co Inc (Symbol: MRK) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-averagestatistics incl...
Merck & Co Inc (Symbol: MRK) has been named as a Top 25 ''Dividend Giant'' by ETF Channel , with a staggering $41.48B worth of stock held by ETFs, and above-ave...
Analyst ratings
52%
of 27 ratingsMore MRK News
If you are thinking in decades and not days, this trio of dividend stocks could be the perfect starting point for your fledgling portfolio. If investing were e...
Merck (MRK) shares have picked up some steam this week, trading higher over the past month. Investors are taking note as the company maintains a steady growth p...
Key Points One of Merck's key assets has just scored a significant phase 2 win, boosting investor confidence. This adds to other recent developments that coul...
Bristol Myers BMY has a robust oncology portfolio, including the blockbuster immune-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others. Opdivo is...